| Literature DB >> 25439696 |
S Vincent Rajkumar1, Meletios A Dimopoulos2, Antonio Palumbo3, Joan Blade4, Giampaolo Merlini5, María-Victoria Mateos6, Shaji Kumar7, Jens Hillengass8, Efstathios Kastritis2, Paul Richardson9, Ola Landgren10, Bruno Paiva11, Angela Dispenzieri7, Brendan Weiss12, Xavier LeLeu13, Sonja Zweegman14, Sagar Lonial15, Laura Rosinol4, Elena Zamagni16, Sundar Jagannath17, Orhan Sezer18, Sigurdur Y Kristinsson19, Jo Caers20, Saad Z Usmani21, Juan José Lahuerta22, Hans Erik Johnsen23, Meral Beksac24, Michele Cavo16, Hartmut Goldschmidt8, Evangelos Terpos2, Robert A Kyle7, Kenneth C Anderson9, Brian G M Durie25, Jesus F San Miguel11.
Abstract
This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and radiographic variables that fulfil the criteria for the presence of myeloma-defining CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specific metrics that new biomarkers should meet for inclusion in the disease definition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any differences in outcome that might occur as a result of the new disease definition.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25439696 DOI: 10.1016/S1470-2045(14)70442-5
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316